Radiation oncology and interventional cardiology firm Implant Sciences said it has been awarded a $750,000 phase II grant from the National Institutes of Health (NIH) for the continued development and clinical evaluation of a radioactive brachytherapy plaque to treat cancerous tumors of the thoracic and lumbar spine.
The brachytherapy plaque is designed to treat the sarcoma cells on the dural surface without harmful dose to the spinal cord. The NIH award provides funding over the next two years and is a follow-on award to an April 2002 phase I $100,000 grant, according to the Wakefield, MA-based company.
This is the second phase of the program and will incorporate improvements to a phase I prototype, including more anatomically correct features and the development of methods to efficiently manufacture the intraoperative radioactive device. The resultant plaque and its dosimetry will be evaluated for clinical utility through a human trial in collaboration with Massachusetts General Hospital in Boston, Implant Sciences said.
By AuntMinnie.com staff writers
April 7, 2005
Related Reading
Implant Sciences gets 510(k) for ytterbium-169, January 27, 2005
Implant Sciences to begin direct sales of brachytherapy seeds, August 7, 2003
Implant Sciences lands NCI development grant, April 25, 2003
Implant Sciences gets NIH grant, April 17, 2003
Implant Sciences gets CE Mark for I-125 brachytherapy seeds, August 2, 2001
Copyright © 2005 AuntMinnie.com
